HDL and LDL : Potential New Players in Breast Cancer Development
Cedó, Lídia (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Reddy, Srinivasa T. (University of California. Department of Molecular and Medical Pharmacology)
Mato, Eugenia (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Escolà-Gil, Joan Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Fecha:	2019
Resumen:	Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality in women. The identification of risk factors can improve prevention of cancer, and obesity and hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work, we review the progress to date in research on the potential role of the main cholesterol transporters, low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although some studies have failed to find associations between lipoproteins and breast cancer, some large clinical studies have demonstrated a direct association between LDL cholesterol levels and breast cancer risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast cancer cells and experimental mouse models of breast cancer have demonstrated an important role for cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate different inflammation-related pathways, thereby enhancing cell proliferation and migration and inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
Ayudas:	Fundació la Marató de TV3 12/C/2015 Instituto de Salud Carlos III FIS18/00164 Instituto de Salud Carlos III FIS16/00139
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Breast cancer ; Cholesterol ; 27-hydroxycholesterol ; HDL ; LDL ; Cholesterol-lowering therapies
Publicado en:	Journal of clinical medicine, Vol. 8, Issue 6 (June 2019) , art. 853, ISSN 2077-0383

DOI: 10.3390/jcm8060853
PMID: 31208017

21 p, 857.5 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados